ELDN Eledon Pharmaceuticals Inc

Price (delayed)

$2.72

Market cap

$221.03M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.91

Enterprise value

$214.69M

?
Relative Growth: Rel. Growth: 0
Relative Strength: Rel. Strength: 52
Relative Valuation: Rel. Valuation: N/A
Relative Profitability: Rel. Profitability: 0

Novus Therapeutics, Inc. is a clinical stage biotechnology company using its expertise in targeting the CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring ...

Highlights
The debt has declined by 42% year-on-year and by 16% since the previous quarter
The company's equity fell by 34% YoY and by 26% QoQ
The net income has contracted by 26% from the previous quarter

Key stats

What are the main financial stats of ELDN

ELDN stock price

How has the Eledon Pharmaceuticals stock price performed over time
Intraday
-5.88%
1 week
1.87%
1 month
-21.16%
1 year
6.67%
YTD
80.13%
QTD
-30.96%

Financial performance

How have Eledon Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$84.6M
Net income
-$99.91M
Gross margin
N/A
Net margin
N/A
The net income has contracted by 26% from the previous quarter
The operating income is up by 3.8% year-on-year and by 2.2% since the previous quarter

Price vs fundamentals

How does ELDN's price correlate with its fundamentals

Growth

What is Eledon Pharmaceuticals's growth rate over time

Valuation

What is Eledon Pharmaceuticals stock price valuation
P/E
N/A
P/B
6.36
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Eledon Pharmaceuticals's EPS has decreased by 18% QoQ
The stock's price to book (P/B) is 35% more than its last 4 quarters average of 5.0
The company's equity fell by 34% YoY and by 26% QoQ

Efficiency

How efficient is Eledon Pharmaceuticals business performance
Eledon Pharmaceuticals's return on equity has decreased by 37% QoQ
The return on invested capital has declined by 31% since the previous quarter
ELDN's return on assets is down by 30% since the previous quarter

Dividends

What is ELDN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ELDN.

Financial health

How did Eledon Pharmaceuticals financials performed over time
The total assets is 133% more than the total liabilities
Eledon Pharmaceuticals's total liabilities has increased by 39% YoY and by 17% from the previous quarter
The total assets has contracted by 14% from the previous quarter and by 13% YoY
The debt is 99% smaller than the equity
The company's debt to equity has shrunk by 50% YoY
The debt has declined by 42% year-on-year and by 16% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.